# US 2025/0152547 A1 · Compositions for delivery of ladostigil

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152547 A1
- Document ID: US20250152547A1
- Status: Published application
- Kind: A1
- Application number: 18/963,641
- Filed: 2024-11-28
- Published: 2025-05-15
- Earliest claimed: 2019-05-28
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem
- Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
- Inventors: Marta WEINSTOCK-ROSIN
- Web page: https://patentgrep.com/patent/US20250152547A1

## CPC

- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions comprising ladostigil, being a colonic delivery composition, including methods and uses thereof.

## Claims

### Claim 1

A method of treating mild cognitive impairment (MCI) in a subject in need thereof, the method comprising orally administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising ladostigil, wherein said pharmaceutical composition is formulated for delivery of said ladostigil to the colon of said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said treating comprises reducing variation in ladostigil blood levels in said subject administered therewith, compared to a control.

### Claim 3 (depends on 2)

The method of claim 2, wherein said reducing variation is by 5-65%, compared to a control.

### Claim 4 (depends on 2)

The method of claim 2, wherein said control is a subject administered with ladostigil formulated for oral delivery.

### Claim 5 (depends on 1)

The method of claim 1, wherein said variation is variation over time.

### Claim 6 (depends on 1)

The method of claim 1, wherein said ladostigil is specifically absorbed in the colon of said subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein said ladostigil is not or minimally absorbed in the upper gastrointestinal (GI) tract, systemically, or both, in said subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein said composition is in a solid dosage form or a semi-solid dosage form.

### Claim 9

A method for reducing variation in ladostigil blood levels in a subject administered therewith, compared to a control, the method comprising orally administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising ladostigil, wherein said pharmaceutical composition is formulated for colonic delivery of ladostigil.

### Claim 10 (depends on 9)

The method of claim 9, wherein said subject is afflicted with MCI.

### Claim 11 (depends on 9)

The method of claim 9, wherein said reducing variation is by 5-65%, compared to said control.

### Claim 12 (depends on 9)

The method of claim 9, wherein said control is a subject administered with ladostigil formulated for oral delivery.

### Claim 13 (depends on 9)

The method of claim 9, wherein said variation is variation over time.

### Claim 14 (depends on 9)

The method of claim 9, wherein said ladostigil is specifically absorbed in the colon of said subject.

### Claim 15 (depends on 9)

The method of claim 9, wherein said ladostigil is not or minimally absorbed in the upper gastrointestinal (GI) tract, systemically, or both, in said subject.

### Claim 16 (depends on 9)

The method of claim 9, wherein said composition is in a solid dosage form or a semi-solid dosage form.
